“Global Small Animal Imaging (In-Vivo) Market is anticipated to grow on account of technological advancements, increasing use of pre-clinical imaging and growing number of research and pharmaceutical companies”, says Visiongain report

05 September 2019
Pharma

Visiongain has launched a new pharma report Small Animal Imaging (In-Vivo) Market Report: By Modality (Optical Imaging, PET, SPECT, CT, MRI, Ultrasound, Photoacoustic Imaging, Magnetic Particle Imaging), Reagent (Optical Imaging Reagents, Contrast Agents, PET Tracers, SPECT Probes) and Region.

Global Small Animal Imaging (In-Vivo) Market is anticipated to grow on account of technological advancements, increasing use of pre-clinical imaging and growing number of research and pharmaceutical companies. The global Small Animal Imaging (In-Vivo) market is anticipated to grow at a lucrative CAGR of 11.3% and anticipated to reach USD 3.32 Billion by 2029.

Small animal imaging (In vitro) is a method used in the imaging of biological procedures in living animals that demonstrates changes in cell activity to study drug effects and progression of disease. Small animal imaging is used for drug development and different disease drug evaluation during clinical studies. Small animal imaging includes digital angiography, micro MRI, micro CT, micro SPECT, X-ray imaging and magnetic particle imaging. Small animal (primarily mice) in vivo imaging is increasingly implemented throughout the drug development phase, especially in the therapeutic area of oncology / cancer.

Currently the most widely used imaging modalities are PET, optical (bioluminescence and fluorescence), and MRI. Single modality imaging prevails, with multi-modality presently being accessed primarily through co-registration with other imaging methods for instance PET+CT. In vivo imaging in research studies is anticipated to have the biggest effect on drug development by tracking the progression of disease and therapeutic reaction. The most commonly used reagents in imaging studies are PET tracers (e.g. Fluorine-18 based) and bioluminescent markers / reporters (e.g. luciferins, proluciferins).  

North America holds majority of market share followed by Europe. Growth is attributed to rising  pre-clinical research, increased public-private investment to promote the manufacturing of radioisotopes, government support for pharmaceutical and biotechnology R&D, and increasing demand for rapid and advanced methods among others. On the other hand, favorable R&D platform and supportive regulatory scenario across Asian economies are stimulating the growth of the small animal imaging market in the region.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global single-cell genomics market. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market.

The comprehensive market report features companies such as Agilent Technologies, Inc., Aspect Imaging, Berthold Technologies, Bioscan, Inc., Bruker Corporation, FUJIFILM Holdings Corporation, Gamma Medica-Ideas, Inc., Genovis Ab, LI-COR Biosciences, Life Technologies Corporation, Mediso Ltd., MILabs B.V., Miltenyi Biotec GmbH, MR Solutions Ltd., PerkinElmer, Inc, Promega Corporation, Inc., Siemens AG, Spectral Instruments Imaging, Thermo Fisher Scientific and Trifoil Imaging among other prominent players.

Also the research study offers market estimation and forecast for the period ranging 2019–2029 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever